Neoadjuvant Keytruda given in a single cycle resulted in a pathological full response fee of 44% in sufferers with poor DNA mismatch restore colon most cancers.
Neoadjuvant Keytruda (pembrolizumab) given in a single cycle was deemed efficacious and protected for sufferers with poor DNA mismatch restore (dMMR) colon most cancers, as proven in outcomes from the part 2 RESET-C trial offered on the 2025 ASCO Gastrointestinal Most cancers Symposium.
A pathological full response (pCR) was famous in 44% (95% CI, 33%-55%) of sufferers and a significant pathological response (mPR) in 57% (95% CI, 46%-68%). For stage 1 or 3, the pCR fee was 61% and for stage 3 it was 33%.
On the survival follow-up date of December 2024, 70 sufferers had a minimal of 1 12 months of follow-up, 57 had a one-year CT scan performed, two had died inside 30 days of surgical procedure and there have been no cases of recurrence.
Grade 3 (extreme) unwanted side effects have been noticed in 8% of sufferers, with 4% experiencing immune-related grade 3 unwanted side effects. Of these included have been two sufferers with hepatitis and one affected person with colitis. There have been no grade 4 (life-threatening) or 5 (demise) immune-related unwanted side effects famous.
Glossary:
Neoadjuvant: remedy given earlier than a fundamental remedy like surgical procedure.
Poor DNA mismatch restore: when the physique’s pure system for correcting errors that happen throughout DNA replication malfunctions, which may result in genomic instability.
Pathological full response: the absence of any remaining invasive most cancers cells in tissue samples eliminated throughout surgical procedure after neoadjuvant remedy.
Main pathological response: a big discount within the variety of viable most cancers cells.
Grade 3a or above Clavien-Dindo: a surgical complication that requires some type of intervention, however not at all times underneath common anesthesia.
Ischemic bowel: when the intestines don’t obtain sufficient blood movement.
General survival: the time from analysis or the beginning of remedy when a affected person with most cancers continues to be alive.
In 31 sufferers (37%), there have been 41 surgical issues noticed. These included grade 3a or above Clavien-Dindo (eight sufferers), and post-operative deaths (two sufferers) at age 80 or above. These deaths have been associated to both gastric stress ulcer-related perforation (one affected person) or ischemic bowel (one affected person).
“Our subsequent step is to combine the outcomes of the endoscopic analysis, re-biopsies, and ctDNA aiming to develop a dependable response evaluation software to pave the trail for a future organ preservation technique,” Dr. Camilla Qvortrup, scientific affiliate professor at Rigshospitalet – Heart for Most cancers and Organ Illness in Denmark, acknowledged through the presentation.
Of the 85 sufferers enrolled, all got Keytruda and included within the security evaluation. One affected person didn’t bear surgical procedure due to their very own needs, so 84 sufferers underwent surgical procedure and have been included within the efficacy evaluation.
To be included, sufferers will need to have dMMR stage 1 to three colon most cancers and haven’t any contraindication for immunotherapy. The first finish level was pCR fee and secondary finish factors included security, surgical issues, mPR and general survival.
Sufferers have been screened at analysis after which included if eligible. They have been then given Keytruda adopted by tumor restaging with a CT scan and colonoscopy. Sufferers then moved to surgical procedure three to 5 weeks after finishing Keytruda remedy with a CT scan as follow-up at one and three years.
“By integrating the outcomes of the re-endoscopy, the biopsies after remedy, and ctDNA, we’re aiming to develop a dependable response evaluation software to pave the trail for a future organ preservation technique,” Qvortrup acknowledged.
The examine posed to reply a number of key questions for this illness state. Beforehand, neoadjuvant immune checkpoint inhibitors had proven constructive ends in dMMR colorectal most cancers. Nonetheless, the optimum period of remedy and response analysis had not but been decided. Investigators believed that the usage of a PD-1 inhibitor for single-cycle remedy would scale back toxicity and prices.
Reference:
Single-cycle neoadjuvant pembrolizumab in sufferers with stage I-III MMR-deficient colon most cancers: ultimate evaluation of the RESET-C examine. Dr. Camilla Qvortrup, et al. J Clin Oncol.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
